Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit?
Department of Genitourinary Medical Oncology, Mount Sinai School of Medicine, Tisch Cancer Institute, New York, New York, USA.
Matthew D
MD
Galsky
Scott T
ST
Tagawa
Shahrokh F
SF
Shariat
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D003142:Communication; D032882:Comprehension; D015653:Cystectomy; D005260:Female; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010353:Patient Education as Topic; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery*
D002945:Cisplatin